search
Back to results

Is Botox Effective in Relieving Pain From Knee Osteoarthritis?

Primary Purpose

Osteoarthritis, Knee

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Botulinum toxin type A (Btx-A)
Cortisone
Sponsored by
Mayo Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis, Knee

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria: A history of knee joint pain for greater than 6 months. Medial or lateral tibiofemoral joint line tenderness. Unilateral knee pain 6/10 or greater, on average, on the visual analog scale (VAS), that interferes with function most days per week. Prior failed treatment with acetaminophen and/or non steroidal anti-inflammatory medications, and physical therapy (quadriceps strengthening). Kellgren grade II or III radiographic changes of osteoarthritis. Exclusion criteria: Age less than 40 years. Anticoagulation with warfarin or heparin. Known allergy or sensitivity to any of the components of the study medications. Body mass index greater than 35. Previous major reconstructive surgery on the affected knee. Previous arthroscopic surgery on the affected knee in the past 12 months. History of crystal induced arthropathy. Use of aminoglycoside antibiotics, curare-like agents, or history of neuromuscular disease such as myasthenia gravis, amyotrophic lateral sclerosis, or myopathy. History of or evidence of active rheumatologic disease, diabetes, severe peripheral neuropathy, clinically evident cardiac or respiratory disease that interferes with functional status, or other serious diseases, including psychiatric disorders. Evidence of recent alcohol or drug abuse, or history of medication misuse or addiction. Females who are pregnant, breastfeeding, or planning a pregnancy during the study, or who think that they may be pregnant at the start of the study, or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study. Intra-articular (knee) or systemic steroids in the past 6 months, or intra-articular knee hyaluronic acid injection in the past 6 months. Patients who rate their average daily pain as less than 6 on a 10 point VAS scale at the screening visit. Concurrent participation in another investigational drug or device study or participation in the 30 days immediately prior to study enrollment.

Sites / Locations

  • Mayo Clinic

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Experimental

Arm Label

Cortisone

Low Dose Btx-A

High Dose Btx-A

Arm Description

Outcomes

Primary Outcome Measures

Decrease in pain at 8 weeks post injection

Secondary Outcome Measures

Improvement in function at 2, 4, 8, 12, 26 weeks
Improvement in quality of life at 2, 4, 8, 12, 26 weeks
Decrease in pain at 2, 4, 12, 26 weeks

Full Information

First Posted
January 18, 2006
Last Updated
November 6, 2012
Sponsor
Mayo Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT00279903
Brief Title
Is Botox Effective in Relieving Pain From Knee Osteoarthritis?
Official Title
Intra-articular Botulinum Toxin Type-A in Knee Osteoarthritis - a Randomized, Cortisone Controlled, Double Blind Study.
Study Type
Interventional

2. Study Status

Record Verification Date
November 2012
Overall Recruitment Status
Completed
Study Start Date
November 2005 (undefined)
Primary Completion Date
August 2008 (Actual)
Study Completion Date
August 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Mayo Clinic

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Patients with painful knee osteoarthritis will be randomly allocated to one of three groups. Each group will receive a knee injection of: 1) cortisone, 2) low dose Botox, or 3) high dose Botox. Patients will then be followed for 6 months to see if they have significant pain relief or improvement in their activity level after the injection.
Detailed Description
Abstract Botulinum toxin type A (Btx-A) has been extensively studied and used clinically for its muscle paralyzing effects, but there is a growing body of evidence to support a role in pain modulation. Symptomatic osteoarthritis is a leading cause of pain, functional impairment, and disability, with significant indirect costs to society. Preliminary evidence suggests that Btx-A has a significant nociceptive effect, when injected intra-articularly, in to painful joints. The proposed study will evaluate the efficacy and safety of Btx-A injected intra-articularly in 60 subjects with moderate pain and functional impairment secondary to knee osteoarthritis, in a randomized, cortisone-controlled, double blind study, over a 6 month follow up period. If Btx-A is shown to be of equal or greater efficacy than cortisone in this patient population, it may be an excellent second line treatment for osteoarthritis, in multiple joints, where surgery is contraindicated or deferred due to age, comorbidities, or patient preference. Further studies examining the mechanism of action at the biochemical level, the clinical effect of Btx-A in other joints (in both osteoarthritis and inflammatory arthritis), the efficacy of Btx-A compared to hyaluronic acid (the only currently available injectable alternative to cortisone), and the side effect profile (effect on adjacent muscle strength, joint position sense, and long-term outcomes) would be indicated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis, Knee

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
62 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cortisone
Arm Type
Active Comparator
Arm Title
Low Dose Btx-A
Arm Type
Experimental
Arm Title
High Dose Btx-A
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Botulinum toxin type A (Btx-A)
Other Intervention Name(s)
Botox
Intervention Description
Participants randomized to Btx-A will be given either a low dose of 100 units or a high dose of 200 units. The Btx-A dose (100U or 200U) will be resonstituted with 4 cc of sterile non-preserved 0.9% sodium chloride solution.
Intervention Type
Drug
Intervention Name(s)
Cortisone
Other Intervention Name(s)
Medrol
Intervention Description
1 cc of 40 mg/cc methylprednisolone will be drawn up in 22 gauge needles with 3 cc of sterile non-preserved 0.9% sodium chloride solution.
Primary Outcome Measure Information:
Title
Decrease in pain at 8 weeks post injection
Secondary Outcome Measure Information:
Title
Improvement in function at 2, 4, 8, 12, 26 weeks
Title
Improvement in quality of life at 2, 4, 8, 12, 26 weeks
Title
Decrease in pain at 2, 4, 12, 26 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: A history of knee joint pain for greater than 6 months. Medial or lateral tibiofemoral joint line tenderness. Unilateral knee pain 6/10 or greater, on average, on the visual analog scale (VAS), that interferes with function most days per week. Prior failed treatment with acetaminophen and/or non steroidal anti-inflammatory medications, and physical therapy (quadriceps strengthening). Kellgren grade II or III radiographic changes of osteoarthritis. Exclusion criteria: Age less than 40 years. Anticoagulation with warfarin or heparin. Known allergy or sensitivity to any of the components of the study medications. Body mass index greater than 35. Previous major reconstructive surgery on the affected knee. Previous arthroscopic surgery on the affected knee in the past 12 months. History of crystal induced arthropathy. Use of aminoglycoside antibiotics, curare-like agents, or history of neuromuscular disease such as myasthenia gravis, amyotrophic lateral sclerosis, or myopathy. History of or evidence of active rheumatologic disease, diabetes, severe peripheral neuropathy, clinically evident cardiac or respiratory disease that interferes with functional status, or other serious diseases, including psychiatric disorders. Evidence of recent alcohol or drug abuse, or history of medication misuse or addiction. Females who are pregnant, breastfeeding, or planning a pregnancy during the study, or who think that they may be pregnant at the start of the study, or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study. Intra-articular (knee) or systemic steroids in the past 6 months, or intra-articular knee hyaluronic acid injection in the past 6 months. Patients who rate their average daily pain as less than 6 on a 10 point VAS scale at the screening visit. Concurrent participation in another investigational drug or device study or participation in the 30 days immediately prior to study enrollment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrea J. Boon, M.D.
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Is Botox Effective in Relieving Pain From Knee Osteoarthritis?

We'll reach out to this number within 24 hrs